Health Economics›Ovarian cancer›Relapsed or recurrent disease platinum-resistant

Relapsed or recurrent disease platinum-resistant

Ovarian cancer · 25 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 17 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Trabectedin monotherapy Variant #01	—	R 103 351	21d	~4.4 mo	~13.7 mo	~2	~R 206 702 PFS proxy · indirect	4
Pegylated liposomal doxorubicin and Trabectedin Variant #01	—	R 77 337	21d	~7.3 mo	~22.2 mo	~2	~R 154 674 PFS proxy · indirect	2
Niraparib monotherapy Variant #01	—	R 68 099	28d	~16.1 mo	—	~39	~R 2 655 867 PFS proxy · indirect	7
Topotecan and Bevacizumab Variant #01	—	R 59 930	28d	~6.7 mo	—	~2	~R 119 861 PFS proxy · indirect	1
Pegylated liposomal doxorubicin and Bevacizumab Variant #01	—	R 54 164	28d	~6.7 mo	~13.0 mo	~2	~R 108 329 PFS proxy · indirect	3
Paclitaxel and Bevacizumab Variant #01	—	R 40 612	28d	~6.7 mo	~13.0 mo	~2	~R 81 225 PFS proxy · indirect	3
Paclitaxel and Pazopanib Variant #01	—	R 24 590	28d	~6.4 mo	—	~2	~R 49 179 PFS proxy · indirect	1
Pazopanib monotherapy Variant #01	—	R 22 754	28d	~17.9 mo	—	~26	~R 591 593 PFS proxy · indirect	1
Olaparib monotherapy Variant #01	HRD	R 19 741	28d	~13.4 mo	~40.9 mo	~2	~R 39 483 PFS proxy · indirect	8
Olaparib monotherapy Variant #01	—	R 19 741	28d	~13.4 mo	~40.9 mo	~2	~R 39 483 PFS proxy · indirect	8
Bevacizumab monotherapy Variant #01	—	R 19 082	14d	~20.4 mo	~51.6 mo	~52	~R 992 271 PFS proxy · indirect	3
Topotecan monotherapy Variant #01	—	R 18 138	21d	~4.0 mo	~13.4 mo	~4	~R 72 553 PFS proxy · indirect	9
Gemcitabine and Pegylated liposomal doxorubicin Variant #01	—	R 15 344	21d	—	—	~2	~R 30 688 indirect	—
Pemetrexed monotherapy Variant #01	—	R 13 225	21d	—	~9.0 mo	~9	~R 119 025 PFS proxy · indirect	2
Pegylated liposomal doxorubicin monotherapy Variant #02	—	R 8 000	28d	~3.9 mo	~13.5 mo	~6	~R 48 000 PFS proxy · indirect	18
Docetaxel monotherapy Variant #02	—	R 2 921	28d	~3.2 mo	~9.5 mo	~8	~R 23 372 PFS proxy · indirect	83
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~3.3 mo	~15.0 mo	~7	~R 11 705 PFS proxy · indirect	4
Etoposide monotherapy Variant #01	—	R 1 231	28d	—	—	~6	~R 7 386 indirect	—
Paclitaxel monotherapy Variant #02	—	R 734	28d	~4.4 mo	~14.0 mo	~7	~R 5 141 PFS proxy · indirect	18
Carboplatin monotherapy Variant #01	—	R 535	21d	5.8 mo	21.0 mo	2	R 1 070 PFS proxy	2
Vinorelbine monotherapy Variant #01	—	R 458	21d	—	~9.0 mo	~7	~R 3 203 PFS proxy · indirect	2
Treosulfan monotherapy Variant #01 Partial	—	—	28d	—	~9.4 mo	~2	—	1
Rucaparib monotherapy Variant #01 Partial	—	—	28d	~20.2 mo	~27.7 mo	~2	—	7
Altretamine monotherapy Variant #01 Partial	—	—	28d	—	—	~6	—	—
Mirvetuximab soravtansine monotherapy Variant #01 Partial	—	—	21d	~5.1 mo	~16.5 mo	~2	—	2

25 of 25 regimens shown